Login to Your Account

Avanir, Novartis Enter $210M Agreement On Inflammation

By Karen Pihl-Carey

Friday, April 29, 2005
Avanir Pharmaceuticals Inc. partnered its first preclinical program, doing so with Novartis AG to develop small-molecule drugs that target macrophage migration inhibitory factor.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription